Simone Marnitz
YOU?
Author Swipe
View article: From Normal to Optimal: Investigating Metabolic and Inflammatory Parameters as Predictors of Survival in Locally Advanced Cervical Cancer
From Normal to Optimal: Investigating Metabolic and Inflammatory Parameters as Predictors of Survival in Locally Advanced Cervical Cancer Open
Cervical cancer is the third most common cancer in women, and recent studies have highlighted the importance of body composition markers in predicting patient outcomes. We build upon the data of 83 patients from the Uterus-11 study, to exp…
View article: Radical vaginal trachelectomy: long-term oncologic and fertility outcomes in patients with early cervical cancer
Radical vaginal trachelectomy: long-term oncologic and fertility outcomes in patients with early cervical cancer Open
Our study confirms oncologic safety of radical vaginal trachelectomy associated with a high chance for childbearing. High rate of pre-term delivery may be due to cervical volume loss. Our long-term oncologic data can serve as a benchmark f…
View article: Optimising (Re-)Irradiation for Locally Recurrent Head and Neck Cancer: Impact of Dose-Escalation, Salvage Surgery, PEG Tube Dependence and Biomarkers on Oncological Outcomes
Optimising (Re-)Irradiation for Locally Recurrent Head and Neck Cancer: Impact of Dose-Escalation, Salvage Surgery, PEG Tube Dependence and Biomarkers on Oncological Outcomes Open
Introduction: Locoregional recurrence (LR) is common in locally-advanced head and neck cancer (HNSCC), posing challenges for treatment. We analysed outcome parameters and toxicities for patients being treated with radiotherapy (RT) for LR-…
View article: Efficacy and Toxicity of Robotic Stereotactic Body Radiotherapy of Lung Metastases in Patients With Oligometastatic Disease
Efficacy and Toxicity of Robotic Stereotactic Body Radiotherapy of Lung Metastases in Patients With Oligometastatic Disease Open
rSBRT is an effective and safe therapy for lung metastases. A BED10 of >100 Gy should be aimed for, especially for potentially radioresistant histologies such as colorectal carcinoma.
View article: Dual-tracer PET/CT protocol with [18F]FDG and [68Ga]Ga-FAPI-46 outperforms single-tracer PET/CT with [18F]FDG in different cancer types, resulting in larger functional and gross tumor volume
Dual-tracer PET/CT protocol with [18F]FDG and [68Ga]Ga-FAPI-46 outperforms single-tracer PET/CT with [18F]FDG in different cancer types, resulting in larger functional and gross tumor volume Open
Purpose Fibroblast activation protein (FAP) detected by positron-emission tomography (PET) using fibroblast activation protein inhibitor (FAPI) appears to be a promising target for cancer imaging, staging, and therapy, providing added valu…
View article: Supplemental Figure 1 from Diagnosis of Pseudoprogression Following Lomustine–Temozolomide Chemoradiation in Newly Diagnosed Glioblastoma Patients Using FET-PET
Supplemental Figure 1 from Diagnosis of Pseudoprogression Following Lomustine–Temozolomide Chemoradiation in Newly Diagnosed Glioblastoma Patients Using FET-PET Open
Supplemental Figure 1 shows increase of time-to-peak supporting the diagnosis of pseudoprogression
View article: Data from Diagnosis of Pseudoprogression Following Lomustine–Temozolomide Chemoradiation in Newly Diagnosed Glioblastoma Patients Using FET-PET
Data from Diagnosis of Pseudoprogression Following Lomustine–Temozolomide Chemoradiation in Newly Diagnosed Glioblastoma Patients Using FET-PET Open
Purpose:The CeTeG/NOA-09 phase III trial demonstrated a significant survival benefit of lomustine–temozolomide chemoradiation in patients with newly diagnosed glioblastoma with methylated O6-methylguanine-DNA methyltransferase (MGMT) promo…
View article: Supplemental Figure 1 from Diagnosis of Pseudoprogression Following Lomustine–Temozolomide Chemoradiation in Newly Diagnosed Glioblastoma Patients Using FET-PET
Supplemental Figure 1 from Diagnosis of Pseudoprogression Following Lomustine–Temozolomide Chemoradiation in Newly Diagnosed Glioblastoma Patients Using FET-PET Open
Supplemental Figure 1 shows increase of time-to-peak supporting the diagnosis of pseudoprogression
View article: Data from Diagnosis of Pseudoprogression Following Lomustine–Temozolomide Chemoradiation in Newly Diagnosed Glioblastoma Patients Using FET-PET
Data from Diagnosis of Pseudoprogression Following Lomustine–Temozolomide Chemoradiation in Newly Diagnosed Glioblastoma Patients Using FET-PET Open
Purpose:The CeTeG/NOA-09 phase III trial demonstrated a significant survival benefit of lomustine–temozolomide chemoradiation in patients with newly diagnosed glioblastoma with methylated O6-methylguanine-DNA methyltransferase (MGMT) promo…
View article: Exercise interventions for adults with cancer receiving radiation therapy alone
Exercise interventions for adults with cancer receiving radiation therapy alone Open
There is little evidence on the effects of exercise interventions in people with cancer who are receiving RT alone. While all included studies reported benefits for the exercise intervention groups in all assessed outcomes, our analyses di…
View article: First Clinical Experience With [68Ga]Ga-FAPI-46-PET/CT Versus [18F]F-FDG PET/CT for Nodal Staging in Cervical Cancer
First Clinical Experience With [68Ga]Ga-FAPI-46-PET/CT Versus [18F]F-FDG PET/CT for Nodal Staging in Cervical Cancer Open
Introduction In several solid tumors, fibroblast activation protein (FAP) is overexpressed by cancer-associated fibroblasts in the tumor microenvironment. Preliminary evidence suggests that detection and staging are feasible with PET/CT im…
View article: The Role of Age and Comorbidities in Esophagogastric Cancer Chemoradiation of the Frail Elderly (>70 Years): An Analysis from a Tertiary High Volume-Center
The Role of Age and Comorbidities in Esophagogastric Cancer Chemoradiation of the Frail Elderly (>70 Years): An Analysis from a Tertiary High Volume-Center Open
Elderly patients > 70 years of age with esophageal cancer (EC) represent a challenging group as frailty and comorbidities need to be considered. The aim of this retrospective study was to evaluate the efficacy and side effects of curative …
View article: P097: The status quo of involved-field radiotherapy – Quality analysis of radiotherapy in the GHSG HD 16
P097: The status quo of involved-field radiotherapy – Quality analysis of radiotherapy in the GHSG HD 16 Open
Question: The HD 16 trial of the German Hodgkin Study Group (GHSG) investigated the use of consolidative radiotherapy (RT) after 2 cycles of ABVD chemotherapy for early-stage Hodgkin lymphoma (HL) and could demonstrate the superiority of a…
View article: P092: Estimating the dosimetric benefit of involved-node radiotherapy in comparison to involved-field radiotherapy - implications from the GHSG HD 17 trial
P092: Estimating the dosimetric benefit of involved-node radiotherapy in comparison to involved-field radiotherapy - implications from the GHSG HD 17 trial Open
Table 1: Size of the planning targe volume (PTV) and dose exposure to organs at risks in comparison between involved-field (IFRT) radiotherapy and involved-node radiotherapy (INRT). Gy: Gray Question: The HD17 trial of the German Hodgkin S…
View article: P093: From involved- field to involved-node – Quality analysis of the radiation therapy in HD 17 by the expert panel of the German Hodgkin Study Group
P093: From involved- field to involved-node – Quality analysis of the radiation therapy in HD 17 by the expert panel of the German Hodgkin Study Group Open
Question: The use of radiotherapy (RT) for intermediate-stage Hodgkin lymphoma is discussed vividly. The HD17 trial of the German Hodgkin Study Group (GHSG) evaluated the value of consolidative involved-node (IN)RT for patients with PET-po…
View article: Teaching in radiation oncology: now and 2025—results of a focus group with medical students
Teaching in radiation oncology: now and 2025—results of a focus group with medical students Open
Purpose In Germany, the new Licensing Regulations for Physicians 2025 (Ärztliche Approbationsordnung, ÄApprO) define a binding legal framework on the basis of which medical faculties modernize their curricula. Since 2015, the National Comp…
View article: S203: ABSCOPAL EFFECT OF RADIOTHERAPY AND NIVOLUMAB IN RELAPSED OR REFRACTORY HODGKIN LYMPHOMA: PRE-PLANNED INTERIM ANALYSIS OF THE INTERNATIONAL GHSG PHASE II AERN TRIAL
S203: ABSCOPAL EFFECT OF RADIOTHERAPY AND NIVOLUMAB IN RELAPSED OR REFRACTORY HODGKIN LYMPHOMA: PRE-PLANNED INTERIM ANALYSIS OF THE INTERNATIONAL GHSG PHASE II AERN TRIAL Open
Background: Failure of anti-PD1 checkpoint blockade in relapsed or refractory Hodgkin lymphoma (r/r HL) constitutes an unmet medical need. It has been postulated that anti-PD1 and localized radiotherapy (RT) may work synergistically to ind…
View article: Toxicity of Dose-Escalated Radiotherapy up to 84 Gray for Prostate Cancer
Toxicity of Dose-Escalated Radiotherapy up to 84 Gray for Prostate Cancer Open
Introduction The outcome of radiotherapy (RT) for prostate cancer (PCA) depends on the delivered dose. While the evidence for dose-escalated RT up to 80 Gy is well established, there have been only few studies examining dose escalation abo…
View article: Dual-tracer PET/CT protocol with [<sup>18</sup>F]-FDG and [<sup>68</sup>Ga]Ga-FAPI-46 for cancer imaging - a proof of concept.
Dual-tracer PET/CT protocol with [<sup>18</sup>F]-FDG and [<sup>68</sup>Ga]Ga-FAPI-46 for cancer imaging - a proof of concept. Open
Imaging studies with PET tracers acting as fibroblast activation protein inhibitors (FAPIs) show promising results that could usefully complement [18F]-FDG in cancer imaging. Methods: All patients received [18F]-FDG PET/CT and dual-tracer …
View article: Oncologic Outcome and Immune Responses of Radiotherapy with Anti-PD-1 Treatment for Brain Metastases Regarding Timing and Benefiting Subgroups
Oncologic Outcome and Immune Responses of Radiotherapy with Anti-PD-1 Treatment for Brain Metastases Regarding Timing and Benefiting Subgroups Open
While immune checkpoint inhibitors (ICIs) in combination with radiotherapy (RT) are widely used for patients with brain metastasis (BM), markers that predict treatment response for combined RT and ICI (RT-ICI) and their optimal dosing and …
View article: Diagnosis, Therapy and Follow-up of Cervical Cancer. Guideline of the DGGG, DKG and DKH (S3-Level, AWMF Registry No. 032/033OL, May 2021) – Part 2 with Recommendationson Psycho-oncology, Rehabilitation, Follow-up, Recurrence, Palliative Therapy and Healthcare Facilities
Diagnosis, Therapy and Follow-up of Cervical Cancer. Guideline of the DGGG, DKG and DKH (S3-Level, AWMF Registry No. 032/033OL, May 2021) – Part 2 with Recommendationson Psycho-oncology, Rehabilitation, Follow-up, Recurrence, Palliative Therapy and Healthcare Facilities Open
Aim This is an update of the interdisciplinary S3-guideline on the Diagnosis, Therapy and Follow-up of Cervical Cancer (AWMF Registry No. 032/033OL), published in March 2021. The work on the updated guideline was funded by German Cancer Ai…